EquiReason

EquiReason research coverage

Indivior Pharmaceuticals, Inc. INDV

Healthcare · Drug Manufacturers - Specialty & Generic

10quarters analysed
12SEC filings read
3segments identified
11institutional managers tracked

Segments it reports

The business segments Indivior Pharmaceuticals, Inc. reports in its own SEC filings.

  • Reportable Segment

Product lines it reports

The product and service lines Indivior Pharmaceuticals, Inc. breaks its revenue into.

  • Sublocade
  • Sublingual And Other
  • Perseris
  • OPVEE

Where its revenue is reported

The geographies Indivior Pharmaceuticals, Inc. reports revenue for. How much comes from each is in the product.

  • United States

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements26
  • Quarterly metric series12
  • Business segments3
  • SEC filings12
  • Deals and transactions5
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks8
  • Estimate revisions11
  • GAAP vs non-GAAP reconciliation1
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series10
  • Margin series1
  • Cash flow series10
  • Earnings series10
  • Per-share series1
  • Operating cash flow series10
  • Guidance changesnot found

This page says how much of Indivior Pharmaceuticals, Inc. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open INDV in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

Indivior Pharmaceuticals, Inc. (INDV) — research coverage | EquiReason